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Due to the rapid development of high-throughput experimental
techniques and fast-dropping prices, many transcriptomic datasets
have been generated and accumulated in the public domain. Meta-
analysis combining multiple transcriptomic studies can increase the
statistical power to detect disease-related biomarkers. In this paper,
we introduce a Bayesian latent hierarchical model to perform tran-
scriptomic meta-analysis. This method is capable of detecting genes
that are differentially expressed (DE) in only a subset of the com-
bined studies, and the latent variables help quantify homogeneous
and heterogeneous differential expression signals across studies. A
tight clustering algorithm is applied to detected biomarkers to cap-
ture differential meta-patterns that are informative to guide further
biological investigation. Simulations and three examples, including a
microarray dataset from metabolism-related knockout mice, an RNA-
seq dataset from HIV transgenic rats, and cross-platform datasets
from human breast cancer, are used to demonstrate the performance
of the proposed method.
1. Introduction. With the rapid development of high-throughput ex-
perimental techniques and fast-dropping prices, many transcriptomic datasets
have been generated and deposited into public databases. In general, each
dataset contains a small to moderate sample size, which requires caution
in gauging the accuracy and reproducibility of detected biomarkers (Simon
et al., 2003; Simon, 2005; Domany, 2014). Meta-analysis combining multi-
ple transcriptomic studies can increase statistical power and provide robust
conclusions from various platforms and sample cohorts (Ramasamy et al.,
2008). Tseng, Ghosh and Feingold (2012) presented a comprehensive review
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2 Z. HUO ET AL.
of methods and applications in the microarray meta-analysis field and cat-
egorized existing methods into combining p-values, combining effect sizes,
direct merging (aka mega-analysis), and combining nonparametric ranks. In
general, meta-analysis can be viewed as two-step information reduction and
combination tools for adjusting batch effects (such as different experimental
platforms, protocols, and bias) across studies to draw a more efficient and
accurate conclusion. This paper focuses on combining p-value methods, and
we will discuss other potential approaches of adjusting batch effects and
directly merging studies in the discussion section.
Following conventions in Birnbaum (1954) and Li and Tseng (2011), two
hypothesis settings have been considered in meta-analysis. In the first setting
(namely HSA), we aim to detect biomarkers that are differentially expressed
(DE) in all studies: H0 : ~θ ∈
⋂{θs = 0} versus HA : ~θ ∈ ⋂{θs 6= 0}, where
θs is the effect size of study s, 1 ≤ s ≤ S. Throughout this manuscript,
effect size refers to unstandardized effect size (Cooper, Hedges and Valentine,
2009) (difference of group means or unstandardized regression coefficients).
In the second setting (HSB), targeted biomarkers are DE in one or more
studies: H0 : ~θ ∈
⋂{θs = 0} versus HA : ~θ ∈ ⋃{θs 6= 0}. In view of overly
stringent criterion in HSA in noisy genomic data and when S is large, Song
and Tseng (2014) proposed a robust setting HSr, requiring that r or more
studies are DE: H0 : ~θ ∈
⋂{θs = 0} versus HA : ~θ ∈∑ I{θs 6= 0} ≥ r, where
I{·} is an indicator function taking value one if the statement is true and
zero otherwise, and r is usually pre-estimated with S/2 ≤ r ≤ S. Song and
Tseng (2014) also proposed using the rth-ordered p-value (rOP, T rOP =
p(r)) to test HSr. Generally speaking, HSA and HSr are most biologically
interesting, because they are designed to detect consensus biomarkers across
the combined studies. However, when heterogeneous differential expression
signals across studies are expected (e.g., studies come from different tissues
or brain regions in the two mouse/rat examples in section 4), biomarkers
detected from HSB can also be of interest. Chang et al. (2013) conducted
a comparative study evaluating twelve popular microarray meta-analysis
methods targeting the three hypothesis settings (HSA, HSB, and HSr).
Strictly speaking, HSB is a sound hypothesis setting, and statistical tests
for HSB are easier to develop. Most popular p-value aggregation methods,
such as Fisher’s method (Fisher, 1934) and Stouffer’s method (Stouffer et al.,
1949), aim for this HSB setting. In the literature, HSB is also called a con-
junction or intersection hypothesis (Benjamini and Heller, 2008). On the
other hand, HSA is a somewhat defective hypothesis setting in the sense that
the null and alternative spaces are not complementary. For example, if we ap-
ply the maximum p-value test (TmaxP = maxs ps, where ps is the p-value for
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study s) for HSA, and we reasonably assume that p-values independently fol-
low UNIF(0,1) under the null hypothesis, then the null distribution of TmaxP
is Beta(S,1). This test is anticonservative when there exist genes DE in some
but not all of the studies. The problem mainly comes from the noncomple-
mentary null and alternative spaces in HSA (and also HSr). A more appro-
priate hypothesis setting for the same purpose is HSA¯ ≡ H0 : ~θ ∈
⋃{θs = 0}
versus HA : ~θ ∈
⋂{θs 6= 0} (and HSr¯ ≡ H0 : ∑ I{θs 6= 0} < r versus
HA :
∑
I{θs 6= 0} ≥ r). Benjamini and Heller (2008) proposed a legitimate
but conservative test for HSA¯ and HSr¯. In genomic applications, the compos-
ite null hypotheses of HSA¯ and HSr¯ are complicated by the fact that genes
can be differentially expressed in up to S − 1 (for HSA¯) or r − 1 (for HSr¯)
studies, with different levels of effect sizes. Under such a scenario, it becomes
very difficult to characterize the null distribution for hypothesis tests in a
frequentist setting. Theoretically it is necessary to borrow differential ex-
pression information across genes to significantly improve statistical power.
Bayesian hierarchical modeling can provide a convenient solution for this
purpose. Efron et al. (2008) and Efron (2009) applied empirical Bayes meth-
ods to control the false discovery rate (FDR) in single microarray studies.
Muralidharan (2010) further extended these works to allow for the simul-
taneous modeling of both empirical null and alternative distribution of the
test statistics. Zhao, Kang and Yu (2014) incorporated pathway information
to select genes using the Bayesian mixture model. Despite these successful
applications, a Bayesian method that combines multiple studies and detects
DE genes based on various meta-analysis hypothesis settings is yet to be
developed. In this paper, we propose a Bayesian latent hierarchical model
(BayesMP, named after the Bayesian method for meta-patterns) that uses
a nonparametric Bayesian method to effectively combine information across
genes for direct testing for HSA¯ (as well as HSB and HSr¯) on a genome-wide
scale. In simulations, we show successful Bayesian false discovery rate con-
trol of BayesMP, while the original maxP and rOP method using a beta null
distribution loses FDR control for the HSA¯ and HSr¯ settings.
Traditionally, meta-analysis aims to pool consensus signals to increase sta-
tistical power (e.g., by fixed or random effects models). Recently, researchers
have recognized the existence of heterogeneous signals among cohorts and
the importance of their characterization in meta-analysis. For example, fig-
ure 1(a) shows three modules of detected biomarkers from the RNA-seq
HIV transgenic rat data using BayesMP and meta-pattern clustering (see
section 4.2 for details). Modules I and II are consensus biomarkers that
are either all down-regulated or all up-regulated across three brain regions.
In contrast, the biomarkers in module III are down-regulated in HIP but
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up-regulated in PFC and STR. Such biomarkers are somewhat expected
because it is well known that different brain regions are responsible for dif-
ferent functions such as reasoning, recognition, visual inspection, and mem-
ory/speech. Several approaches, such as the adaptive weighting (or subset)
method (Li and Tseng, 2011; Bhattacharjee et al., 2012) and lasso variable
selection (Li et al., 2014), have been proposed for quantifying and inferring
such heterogeneity. In the adaptively weighted Fisher’s method (AW-Fisher;
Li and Tseng 2011), for example, heterogeneity of differential expression sig-
nals in each study is categorized by wgs as 0 or 1 weights (1 representing
differential expression for gene g in study s, and 0 for nondifferential ex-
pression). Specifically, AW-Fisher considers weighted Fisher’s statistics —
that is, T ( ~Wg) = −2
∑S
s=1wgs · log(pgs), where ~Wg = (wg1, . . . , wgS) is the
vector of 0 or 1 weights reflecting gene-specific heterogeneous contribution
of each study and pgs is the p-value of gene g in study s — and adap-
tively searches the best weight vector for gene g by minimizing the resulting
p-value: ~̂Wg = arg min ~Wg p(T (
~Wg)) = arg min ~Wg 1 − F
−1
χ2
2·∑Ss=1 wgs
(T ( ~Wg)),
where F−1
χ2w
is the inverse CDF of chi-squared distribution with degree of
freedom w. The 0 or 1 weights estimated from AW-Fisher help cluster de-
tected biomarkers by their differential expression meta-patterns but have
a disadvantage of hard-thresholding without quantification of variability.
When S is large, the number of all possible 2S − 1 weight combinations also
makes the problem intractable. In BayesMP, the differential expression indi-
cators naturally come with variability estimates from posterior distribution
(see a confidence score to be defined later in section 2.3). In BayesMP, we
also adopt a cosine dissimilarity measure on these posterior distributions and
apply tight clustering (Tseng and Wong, 2005) to identify biomarkers of dif-
ferent meta-patterns (e.g., see the three modules of biomarkers in figure 1).
Unsupervised clustering of the expression pattern across studies identifies
data-driven modules of biomarkers of different meta-patterns and provides
interpretable results for further biological investigation. For example, it is
interesting to investigate why biomarkers in module III are down-regulated
in HIP but up-regulated in PFC and STR. We note here that our proposed
cluster analysis to categorize detected biomarkers by studying heterogeneity
in meta-analysis is a relatively novel concept. It is different from popular
practices of clustering genes for identifying coexpression gene modules or
clustering samples for discovering disease subtypes (e.g., Huo et al. (2016)).
In this paper, section 2 establishes the methodology, estimation, and in-
ference of BayesMP. Section 3 evaluates the performance of the proposed
method using simulation datasets. Section 4 shows the application to three
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Fig 1. Three meta-pattern modules of biomarkers from HIV transgenic rats example. Each
row (module I, II, and III) shows a set of detected biomarkers showing similar meta-pattern
of differential signals. 1(a) Heatmaps of detected genes (on the rows) and samples (on the
columns) for each brain region (HIP, PFC, or STR), where each brain region represents
a study (i.e., HIP for s = 1, PFC for s = 2, STR for s = 3). The black color bar on
top represents F334 rats (control), and the red color bar on top represents HIV transgenic
rats (case). 1(b) Heatmaps of confidence scores (CS) (genes on the rows and three studies
on the columns). The confidence score is described in section 2.3, which ranges from -1
(blue color for down-regulation) to 1 (red color for up-regulation). 1(c) Bar plots of mean
posterior probability for Ygs = 1 (red color for up-regulation) and Ygs = −1 (blue color
for down-regulation) for each module in each brain region. Error bar represents standard
deviation across all genes in the module. The number of genes is shown on top of each bar
plot.
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real examples. Finally, section 5 provides conclusions and discussions.
2. Methods. For the ease of discussion, we focus on detecting DE genes
in two-class comparison in this manuscript. The method can be easily ex-
tended for studies with numerical or survival outcomes. In a meta-analysis
combining S studies with G genes, we denote pgs as the one-sided p-value
testing for down-regulation for gene g in study s, where 1 ≤ g ≤ G and
1 ≤ s ≤ S. These p-values can be calculated from SAM (Tusher, Tibshirani
and Chu, 2001) or limma (Smyth, 2005) for microarray studies (or RNA-seq
studies with RPKM data), and edgeR (Robinson, McCarthy and Smyth,
2010) or DEseq (Anders and Huber, 2010) for RNA-seq studies with count
data. As a result, our model is flexible to mixed studies of different plat-
forms (e.g., microarray or RNA-seq) and study designs (e.g., case-control,
numerical outcome, or survival outcome). Throughout this manuscript, we
use limma and edgeR to obtain the p-values. For modeling convenience,
we transform the one-sided p-values into Z -statistics, i.e. Zgs = Φ
−1(pgs),
where Φ−1(·) is the inverse cumulative density function (CDF) of standard
Gaussian distribution. Zgs is the input data for BayesMP.
2.1. Bayesian hierarchical mixture model. Denote by θgs the effect size of
gene g in study s and by Ygs an indicator variable s.t. Ygs = 1 if θgs > 0 (up-
regulation), Ygs = −1 if θgs < 0 (down-regulation), and Ygs = 0 if θgs = 0
(non-DE gene). We assume that the Z -statistics from study s are sampled
from a mixture distribution with three mixing components depending on Ygs:
f (s)(Zgs|Ygs) = f (s)0 (Zgs)·I(Ygs = 0)+f (s)+1 (Zgs)·I(Ygs = 1)+f (s)−1 (Zgs)·I(Ygs =
−1), where f (s)(·) is the pdf of Z -statistics in study s, and f (s)0 , f (s)+1 and
f
(s)
−1 are the pdfs of the null, positive, and negative components in study s.
In most situations, if an appropriate statistical test is adopted, one can
expect that pgs ∼ Unif(0, 1) if gene g in study s is not DE and hence rea-
sonably assume f
(s)
0 ≡ N(0, 1). If the p-value distribution is not uniform
under null hypothesis, one can also empirically estimate f
(s)
0 following Efron
(2004). Throughout this manuscript, we use theoretical null N(0, 1), and
we put discussion about this choice in the conclusion section. Unlike f
(s)
0 ,
f
(s)
±1 are usually unknown, and their estimation is not trivial. To account for
the complex composition of alternative f
(s)
±1 (potentially several subgroups
exist in the alternative space), we model them nonparametrically by assum-
ing they are also mixtures of distributions using Dirichlet processes (DPs).
DPs are widely discussed and applied in the literature (Neal, 2000; Mu¨ller
and Quintana, 2004), and density estimation using DPs has also been dis-
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cussed (Escobar and West, 1995). In our model, when Ygs 6= 0, we assume
Zgs ∼ N(µgs, 1), and µgs follows distribution Gs+ or Gs− generated from
DPs. Specifically, the generative process of Zgs given Ygs = ±1 is as follows:
Gs+ ∼ DP(G0+, α+) and Gs− ∼ DP(G0−, α−).
µgs ∼
{
Gs+ if Ygs = 1,
Gs− if Ygs = −1.
Zgs ∼ N(µgs, 1).
DP(G,α) denotes a Dirichlet process with base distribution G and con-
centration parameter α, and G0+ (G0−) denotes normal density N(0, σ20)
left (right) truncated at 0. We find that the selection of σ0 and α± do not
much affect the performance of this model in simulation [see details in sup-
plementary table S3 (Huo, Song and Tseng, 2018)]. It should be noted that
we assume Zgs ∼ N(µgs, 1), where the variance is fixed at 1 to ensure that
f
(s)
+1/f
(s)
0 (f
(s)
−1/f
(s)
0 ) is monotonically increasing (decreasing) while Zgs > 0
(Zgs < 0), which in turn guarantees the posterior probability of gene g
being DE in study s to increase as |Zgs| increases (see Theorem 2.1). In
addition, this assumption makes the MCMC simpler and hence speeds up
the algorithm.
Theorem 2.1. If fk(x) ≡ N(µk, σ2k) with µk > 0, σ2k ≥ 1 and 1 ≤ k ≤ K,
and f0(x) = N(0, 1), then
∑K
k=1wkfk/f0 is monotonically increasing when
x ≥ 0, where w1, . . . , wK > 0 and
∑K
k=1wk = 1.
Proof. ∀1 ≤ k ≤ K, fk(x) = 1/(σk
√
2pi) exp(−(x−µk)2/(2σ2k)), f0(x) =
1/
√
2pi exp(−x2/2), So gk(x) = fk(x)/f0(x) = 1/σk exp(−(x−µk)2/(2σ2k))+
x2/2) and log gk(x) = −(x−µk)2/(2σ2k)+x2/2− log σk. By taking derivative
of log gk(x), we get [log gk(x)]
′ = −(x−µk)/σ2k+x = (1−1/σ2k)x+µk/σ2k > 0,
when x ≥ 0 (actually x > µk/(1 − σ2k) is enough). Therefore gk = fk/f0 is
monotonically increasing when x ≥ 0, and ∑Kk=1wkfk/f0 is also monotoni-
cally increasing when x ≥ 0.
In order to borrow information across studies, we further assume that Ygs
is generated depending on (1) the prior probability pig that gene g is a DE
gene and (2) the conditional probability δg for gene g in study s being up-
regulated (or 1− δg for down-regulated), given gene g is DE. Specifically, we
assume ~Wgs ∼ Mult
(
1, (1− pig, pi+g , pi−g )
)
and Ygs = ~Wgs · (0, 1,−1), where
pi+g = pigδg, pi
−
g = pig(1− δg) and · is the inner product of two vectors. Given
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Ygs = y, Zgs is generated from f
(s)
y (Z). The graphical representation of the
full generative model is shown in figure 2.
We assume that each gene g is DE in different studies in the same proba-
bility pig, i.e., pig = Pr(Ygs 6= 0), and pig ∼ Beta(γ, 1−γ). γ can be interpreted
as the proportion of DE genes pooling all studies, since the expectation of pig
from this prior is γ. We further set the prior of γ being uniform distribution
(γ ∼ UNIF(0, 1)).
For each gene g, define δg = Pr(Ygs = 1|gene g is a DE gene). We assume
δg ∼ Beta(β, β). We set β = 1/2 in this paper, which gives a noninformative
prior. Note that this conditional probability provides flexibility for a DE gene
to contain conflicting differential expression directions (i.e., up-regulation in
one study but down-regulation in another study; e.g., module III in figure 1)
πg δg 
Ygs 
Zgs 
G0+ G0- 
Gs+ Gs- 
fk-(s) fk+(s) f0 
f(s)	
γ β α 
Fig 2. Graphical representation of Bayesian latent hierarchical model. Shaded nodes are
observed variables. Dashed nodes are pre-estimated/fixed parameters. Arrows represent
generative process. Dashed lines represent equivalent variables. s is the study index, and g
is the gene index.
2.2. Model fitting. Since conjugate priors were used in the generative
model, we can generate the posterior samples efficiently using the MCMC
procedure. In order to update the DP with an infinite number of compo-
nents, we take the alternative view of DP as the Chinese restaurant process.
We define Cgs ∈ {. . . ,−3,−2,−1, 0, 1, 2, 3, . . .} as the auxiliary component
variable, and Ygs is determined by the sign of Cgs. Specifically, if Cgs = 0,
we set Ygs = 0; if Cgs = k with k > 0, then we set Ygs = 1, and sample
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µgs from the kth component (or kth table in Chinese restaurant process) of
Gs+; and similarly, if Cgs = k with k < 0, then we set Ygs = −1 and sample
µgs from the kth component of Gs−. The following steps provide details of
our MCMC iterations:
1. Update pig’s:
pig|Ygs ∼ Beta(γ + Y +g + Y −g , S − Y +g − Y −g + 1− γ),
where Y +g =
∑
s I(Ygs = 1) and Y −g =
∑
s I(Ygs = −1).
2. Update δg’s:
δg|Ygs ∼ Beta(β + Y +g , β + Y −g ).
3. Update Ygs’s:
First update Cgs’s s.t.
Pr(Cgs = k|C−g,s, Zgs, pi±g ) ∝ h(s)k (Zgs|C−g,s)(pi+g )I(k>0)(pi−g )I(k<0)(1−pig)I(k=0),
where C−g,s denotes all the C’s in study s excluding gene g. Note
that h
(s)
k can be calculated directly following the convention of algo-
rithm 3 in Neal (2000). Details of h
(s)
k (Zgs|C−g,s) are given in sup-
plementary section III (Huo, Song and Tseng, 2018). Finally, we set
Ygs = sgn(Cgs), where sgn(·) is the sign function.
4. Because there is no immediate conjugate prior for γ, we sample γ using
the Metropolis-Hastings algorithm such that
γ ∝
G∏
g=1
dBeta(pig; γ, 1− γ),
where dBeta(x; a, b) is the probability density function of beta distri-
bution evaluated at x, with the shape parameters a and b. For details
see supplementary section I (Huo, Song and Tseng, 2018).
2.3. Decision space and inference making. A main benefit of Bayesian
modeling is its capability of making inference by statistical decision theory, a
generalized framework that covers the traditional hypothesis testing frame-
work as a special case (Berger, 2013). Take HSA¯ from section 1 as an exam-
ple. Traditional hypothesis testing considers null hypothesis H0 : ~θg ∈ Ω0A¯,
where Ω0
A¯
= {~θg :
∑S
s=1 I(θgs 6= 0) < S} and ~θg = (θg1, · · · , θgS), versus al-
ternative hypothesis HA : ~θg ∈ Ω1A¯ where Ω1A¯ = {~θg :
∑S
s=1 I(θgs 6= 0) = S}.
When observed data are unlikely to happen (i.e., type I error controlled at
5%) under null hypothesis, we reject the null hypothesis. One notable feature
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is that traditional hypothesis testing views null and alternative hypothesis
spaces differently. The decision of hypothesis testing is only based on the
null hypothesis — either to reject or to accept. The alternative hypothesis
plays little role in decision making. In view of decision theory framework,
a decision space (aka action space) is designed as DA¯ = (Ω0A¯,Ω1A¯). The in-
ference generates a decision function f that maps from the observed data
space Z to DA¯ (i.e., f : Z → DA¯). Under this framework, the type I er-
ror can be expressed as Pr(f(Z) = Ω1
A¯
|~θg ∈ Ω0A¯), and the type II error as
Pr(f(Z) = Ω0
A¯
|~θg ∈ Ω1A¯). Hypothesis testing is a special case under this
framework, with adequate type I error control to determine the decision
function f . Unlike hypothesis testing, decision theory treats Ω0
A¯
and Ω1
A¯
equally, because in decision theory, the decision is made through cost anal-
ysis, which weighs the costs of making wrong decisions in both spaces. One
can easily design a realistic loss (cost) function based on the two types of
errors to determine their balance and achieve the best decision function.
In this paper, in order to make a fair comparison with classical hypothesis
testing, we use posterior probabilities from Bayesian modeling and adopt a
false discovery control described by Newton et al. (2004) to determine the
decision function.
Denote by ξg = Pr(~θg ∈ Ω0A¯|Z) = 1− Pr(~θg ∈ Ω1A¯|Z), which is local FDR
(Efron and Tibshirani, 2002) by definition. Given a threshold κ, we declare
gene g as a DE gene if ξg ≤ κ and the expected number of false discover-
ies is
∑
g ξgI(ξg ≤ κ). The false discovery rate from Bayesian modeling is
defined as
∑
g ξgI(ξg≤κ)∑
g I(ξg≤κ) (Newton et al., 2004). In simulation and real data
applications, we compare the performance of FDR control from traditional
hypothesis testing and FDR control from Bayesian modeling. Note that we
can consider DB = (Ω0B,Ω1B), where Ω0B = {~θg :
∑S
s=1 I(θgs 6= 0) = 0} and
Ω1B = {~θg :
∑S
s=1 I(θgs 6= 0) > 0}, to correspond to HSB; and Dr¯ = (Ω0r¯ ,Ω1r¯),
where Ω0r¯ = {~θg :
∑S
s=1 I(θgs 6= 0) < r} and Ω1r¯ = {~θg :
∑S
s=1 I(θgs 6= 0) ≥
r}, to correspond to HSr¯.
Finally, for a declared DE gene, we are given the posterior probability
of whether gene g in study s is a non-DE gene (Pr(Ygs = 0|Z)), an up-
regulated gene (Pr(Ygs = 1|Z)), or a down-regulated gene (Pr(Ygs = −1|Z)).
We propose a gene- and study-specific confidence score Vgs = Pr(Ygs =
1|Z) − Pr(Ygs = −1|Z), which ranges between −1 and 1. We are confident
that gene g is up-regulated in study s if Vgs is close to 1, and vice versa
when Vgs is close to −1. See figure 1(b) for an example.
2.4. Biomarker clustering for meta-patterns of homogenous and heteroge-
nous differential signals. Several recently developed meta-analysis meth-
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ods (Li and Tseng, 2011; Bhattacharjee et al., 2012; Li et al., 2014) provide
modeling of homogeneous and heterogeneous differential signals. The 0 or
1 differential expression indicators (e.g., ~wg in AW-Fisher) allow further
biological investigation on consensus biomarkers as well as study-specific
biomarkers. However, when S becomes large, the number of biomarker cat-
egories grows exponentially to 2S − 1, and the biomarker categories become
intractable. In BayesMP, the posterior probability of the differential expres-
sion indicator (i.e., Pr(Ygs|Z)) provides probabilistic soft conclusions. After
we obtain a list of biomarkers under certain global FDR control (e.g., 5%
or 1%), we apply the tight clustering algorithm (Tseng and Wong, 2005) to
generate data-driven biomarker modules. Tight clustering is a resampling-
based algorithm built upon K-means or K-medoids. This method aggregates
information from repeated clustering of subsampled data to directly identify
tight clusters (i.e., sets of biomarkers with small dissimilarity) and does not
force every biomarker into a cluster. It can be applied to any dissimilarity
matrix if K-medoids is used. Pathway enrichment analysis is then applied
to functionally annotate each biomarker module. The resulting biomarker
modules of different meta-patterns will greatly facilitate interpretation and
hypothesis generation for further biological investigation. In the first two real
data applications, for example, heterogeneous meta-patterns of biomarkers
are expected from the nature of multi-tissue or multi-brain-region design
across studies. Biomarkers up-regulated in one brain region but non-DE (or
even down-regulated) in another brain region is of great interest. It should
be noted that in the third breast cancer data application, meta-patterns
still help characterize the heterogeneity of different cohorts (e.g., differences
of study population and probe design), even though this heterogeneity is
hopefully minimal since these studies focus on the same disease with homo-
geneous tissue type.
To apply tight clustering, we need to define a dissimilarity measure for
any pair of genes. Denote by ~Ugs the posterior probability vector for Ygs:
~Ugs = (Pr(Ygs = 1|Z),Pr(Ygs = −1|Z),Pr(Ygs = 0|Z)), which can be es-
timated by MCMC samples. For two genes i and j, we first calculate the
dissimilarity of ~Uis and ~Ujs in study s and then average over study index s.
The dissimilarity measure between ~Uis and ~Ujs we considered includes cosine
dissimilarity, l2 dissimilarity, l22D dissimilarity, symmetric KL dissimilarity,
and Hellinger dissimilarity. Definitions and details of these dissimilarity mea-
surements are in supplementary section II (Huo, Song and Tseng, 2018). By
using the simulation setting in section 3.2, we found cosine dissimilarity
outperforms others [see details in supplementary figure S3 Huo, Song and
Tseng (2018)], and hence adopted it in our paper and would recommend it
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for other applications.
3. Simulation results.
3.1. DE gene detection and FDR control. To evaluate the performance
of the proposed method and compare to other methods, we performed the
simulations below:
1. Let S be the number of studies, G = 10, 000 be the total number of
genes, and N = 20 be the number of cases and controls (2N samples
in total).
2. We firstly focus on simulating gene correlation structure and assume no
effect size for all genes in all studies. We sample expression levels with
correlated genes following the procedure in Song and Tseng (2014).
(a) Sample 200 gene clusters with 20 genes in each cluster, and the re-
maining 6,000 genes are uncorrelated. Denote by Cg ∈ {0, 1, . . . , 200}
the cluster membership indicator for gene g, for example, Cg = 1
indicates gene g is in cluster 1, whereas Cg = 0 indicates gene g
is not in any gene cluster.
(b) For cluster c and study s, sample A′cs ∼ W−1(Ψ, 60), where
1 ≤ c ≤ 200, Ψ = 0.5I20×20 + 0.5J20×20, W−1 denotes the in-
verse Wishart distribution, I is the identity matrix, and J is the
matrix with all elements equal to 1. Then Acs is calculated by
standardizing A′cs such that the diagonal elements are all 1s. The
covariance matrix for gene cluster c in study s is calculated as
Σcs = σ
2Acs, where σ is a tuning parameter we vary in the eval-
uation.
(c) Denote by gc1, . . . , gc20 the indices of the 20 genes in cluster c (i.e.
Cgcj = c, where 1 ≤ c ≤ C(C = 200), and 1 ≤ j ≤ 20). Sample
expression levels of genes in cluster c for sample n in study s
as (X ′gc1sn, . . . , X
′
gc20sn) ∼ MVN(0,Σcs), where 1 ≤ n ≤ 2N and
1 ≤ s ≤ S. For any uncorrelated gene g with Cg = 0, sample
the expression level for sample n in study s as X ′gsn ∼ N(0, σ2),
where 1 ≤ n ≤ 2N and 1 ≤ s ≤ S.
3. Sample DE genes, effect sizes, and their differential expression direc-
tions.
(a) Assume that the first G1 genes are DE in at least one of the com-
bined studies, where G1 = 30%×G. For each 1 ≤ g ≤ G1, sample
vg from discrete uniform distribution vg ∼ UNIF(1, . . . , S), and
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then randomly sample subset vg ⊆ {1, . . . , S} such that |vg| = vg.
Here vg is the set of studies in which gene g is DE.
(b) For any DE gene g (1 ≤ g ≤ G1), sample gene-level effect size
θg ∼ N0.5+(1, 1), where Na+ denotes the truncated Gaussian dis-
tribution within interval (a,∞). For any s ∈ vg, also sample
study-specific effect size θgs ∼ N0+(θg, 0.22).
(c) Sample dg ∼ Ber(0.5), where 1 ≤ g ≤ G1 and s ∈ vg. Here dg
controls effect size direction for gene g.
4. Add the effect sizes to the gene expression levels sampled in step 2c.
For controls (1 ≤ n ≤ N), set the expression levels as Xgsn = X ′gsn. For
cases (N + 1 ≤ n ≤ 2N), if 1 ≤ g ≤ G1 and s ∈ vg, set the expression
levels as Xgsn = X
′
gsn + (−1)dgθgs; otherwise, set Xgsn = X ′gsn.
We performed simulation with S = 3, 5, 10 and σ = 1, 2, 3 to account for
different numbers of combined studies and various signal/noise ratio. We ap-
plied limma to compare the gene expression levels between the control group
and the case group. We transformed the two-sided p-values from limma to
one-sided p-values by taking account of the directions of estimated effect
sizes. Then one-sided p-values are transformed to Z statistics. BayesMP took
53 minutes on a regular PC with 1.4 GHz CPU (i.e., for one simulation with
S = 3 and σ = 1) to obtain 10,000 posterior samples using MCMC. Supple-
mentary figure S1 (Huo, Song and Tseng, 2018) shows the posterior samples
of pig in two example genes — a DE gene and a non-DE gene as well as
γ. Because the posterior samples converge to a stationary distribution very
quickly for our method [see examples in supplementary figure S1 (Huo, Song
and Tseng, 2018)], excluding 500 posterior samples for burn-in is enough for
the analyses of this paper. We repeated the simulation 100 times and aver-
aged the results. We compared the performance of our method and existing
methods designed for decision space DA¯ (maxP), DB (Fisher’s method and
AW), and Dr¯ (rOP) with r = bS/2c + 1 using false discovery rate (FDR),
false negative rate (FNR), and the area under the curve (AUC) of the re-
ceiver operating characteristic (ROC) curve. Note that in our comparison,
we used DA¯ and Dr¯ which are equivalent to the complementary hypothesis
testings HSA¯ and HSr¯, and the true number of studies in which a gene is
DE can be calculated because the truth is known in simulation. Table 1
compares the FDR, FNR, and AUC of different methods at nominal FDR
level 5%, which is widely accepted in genomic research. For decision space
DB, all the three methods controlled FDR around its nominal level, which
is anticipated because HSB is complementary and equivalent to DB. Fisher
and AW were slightly overconservative in terms of FDR control — Fisher’s
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method and AW controlled FDR at around 3.5%, whereas our BayesMP
controlled FDR at around the nominal 5%. This phenomenon has also been
observed in Song and Tseng (2014) when the genes are correlated. Because
BayesMP is less conservative than the other two methods, we were able to
detect slightly more genes under DB. In addition, BayesMP achieved similar
(or slightly better) FNR and AUC with Fisher and AW under DB. Fisher’ s
method is known to be almost optimal — that is, Fisher’ s method achieves
asymptotic Bahadur optimality (ABO) (Littell and Folks, 1971) when ef-
fect sizes are consistent and equal for all studies. This indicated BayesMP
is also almost optimal for DB under the simulation scenario. For decision
space DA¯ and Dr¯, we observed that maxP and rOP lost control of FDR. As
discussed in section 1, this is caused by the nature that HSA and HSr have
noncomplementary null and alternative spaces. To the contrary, BayesMP
still controlled FDR close to its nominal level for DA¯ and Dr¯. Note that
because maxP and rOP were not able to control FDR at its nominal level,
the number of genes detected by these methods was not directly comparable
to our methods. However, FNR of BayesMP was only slightly larger than
rOP for Dr¯, regardless of the conservative FDR control. When S was large
(S = 10) in simulation, the FDR control of BayesMP under DA¯ deviated
from its nominal level (around 10% instead of 5%). The reason for the anti-
conservative control was that the data simulation setting was different from
model generative process, thus small errors accumulated when S got large.
However, BayesMP still performed much better than maxP and roP (FDR
= 0.58 for maxP in DA¯ and FDR = 0.23 for rOP in Dr¯ setting). In addition,
BayesMP achieved much larger AUC than maxP and rOP under DA¯ and
Dr¯, which indicated better predictive power of BayesMP.
3.2. Simulation to evaluate meta-pattern gene module detection. To eval-
uate the performance of gene module detection, we adopted a simulation pro-
cedure similar to section 3.1. We simulated S = 4 studies in total. Among
the G = 10, 000 genes, we set 4% of them as homogeneously concordant DE
genes, with the same direction in all studies (all positive or all negative). We
denote “homo+” as the homogeneously concordant DE genes with all pos-
itive effect sizes and “homo−” as the homogeneously concordant DE genes
with all negative effect sizes. We also set another 4% of all genes as study-
specific DE genes — differentially expressed only in one study. Among them,
1/4 are DE genes only in the first study with positive effect sizes (denoted as
“ssp1+”), 1/4 are DE genes only in the first study with negative effect sizes
(denoted as “ssp1−”), 1/4 are DE genes only in the second study with pos-
itive effect sizes (denoted as “ssp2+”), and the remaining 1/4 are DE genes
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Table 1
Comparison of different methods by FDR, FNR, and AUC of ROC curve for decision
spaces DA¯, DB, and Dr¯. The nominal FDR is 5% for all compared methods. The mean
results and SD (in parentheses) were calculated based on 100 simulations.
DA¯ DB Dr¯ (r = bS/2c+ 1)
S σ BayesMP maxP BayesMP Fisher AW BayesMP rOP
FDR
3
1
0.058 0.207 0.042 0.035 0.035 0.034 0.086
(0.008) (0.014) (0.004) (0.005) (0.004) (0.004) (0.007)
2
0.058 0.198 0.047 0.035 0.036 0.037 0.080
(0.010) (0.017) (0.006) (0.006) (0.006) (0.005) (0.009)
3
0.043 0.184 0.050 0.035 0.036 0.036 0.073
(0.016) (0.025) (0.009) (0.008) (0.009) (0.009) (0.014)
5
1
0.075 0.361 0.043 0.034 0.034 0.037 0.130
(0.011) (0.017) (0.004) (0.004) (0.004) (0.005) (0.008)
2
0.079 0.349 0.046 0.034 0.034 0.042 0.115
(0.019) (0.022) (0.006) (0.005) (0.005) (0.006) (0.010)
3
0.062 0.330 0.050 0.034 0.034 0.042 0.099
(0.033) (0.028) (0.007) (0.006) (0.007) (0.008) (0.013)
10
1
0.105 0.580 0.050 0.035 0.035 0.047 0.231
(0.017) (0.021) (0.003) (0.004) (0.004) (0.005) (0.010)
2
0.122 0.569 0.050 0.035 0.035 0.059 0.200
(0.029) (0.027) (0.005) (0.005) (0.005) (0.007) (0.012)
3
0.108 0.554 0.054 0.035 0.035 0.062 0.167
(0.064) (0.044) (0.007) (0.006) (0.006) (0.010) (0.015)
FNR
3
1
0.024 0.017 0.054 0.058 0.056 0.039 0.032
(0.002) (0.001) (0.003) (0.003) (0.003) (0.002) (0.002)
2
0.064 0.055 0.170 0.181 0.183 0.114 0.112
(0.002) (0.002) (0.003) (0.003) (0.003) (0.003) (0.003)
3
0.089 0.082 0.240 0.253 0.257 0.161 0.166
(0.003) (0.002) (0.002) (0.002) (0.002) (0.003) (0.003)
5
1
0.016 0.009 0.043 0.048 0.045 0.032 0.021
(0.001) (0.001) (0.003) (0.002) (0.003) (0.002) (0.001)
2
0.040 0.031 0.150 0.162 0.164 0.092 0.086
(0.002) (0.002) (0.003) (0.003) (0.003) (0.002) (0.002)
3
0.054 0.047 0.219 0.236 0.241 0.132 0.136
(0.002) (0.002) (0.003) (0.003) (0.003) (0.002) (0.003)
10
1
0.009 0.004 0.030 0.035 0.031 0.027 0.010
(0.001) (0.001) (0.002) (0.002) (0.002) (0.001) (0.001)
2
0.022 0.015 0.119 0.132 0.132 0.070 0.054
(0.001) (0.001) (0.003) (0.003) (0.003) (0.002) (0.002)
3
0.028 0.023 0.184 0.206 0.211 0.097 0.095
(0.002) (0.002) (0.003) (0.002) (0.003) (0.003) (0.003)
AUC
3
1
0.976 0.926 0.973 0.973 0.973 0.980 0.972
(0.003) (0.003) (0.002) (0.002) (0.002) (0.002) (0.003)
2
0.906 0.876 0.880 0.878 0.876 0.902 0.873
(0.006) (0.006) (0.005) (0.005) (0.005) (0.005) (0.006)
3
0.833 0.806 0.788 0.784 0.780 0.820 0.776
(0.008) (0.008) (0.006) (0.006) (0.006) (0.007) (0.008)
5
1
0.974 0.920 0.978 0.978 0.979 0.985 0.979
(0.004) (0.003) (0.002) (0.002) (0.002) (0.002) (0.002)
2
0.918 0.891 0.896 0.893 0.892 0.928 0.893
(0.007) (0.006) (0.004) (0.004) (0.004) (0.004) (0.004)
3
0.866 0.833 0.812 0.805 0.800 0.859 0.801
(0.009) (0.009) (0.005) (0.005) (0.006) (0.005) (0.006)
10
1
0.964 0.910 0.985 0.983 0.985 0.985 0.986
(0.007) (0.003) (0.002) (0.002) (0.002) (0.002) (0.002)
2
0.907 0.905 0.920 0.917 0.917 0.948 0.920
(0.010) (0.006) (0.004) (0.004) (0.004) (0.004) (0.004)
3
0.883 0.865 0.849 0.840 0.835 0.907 0.838
(0.011) (0.009) (0.005) (0.005) (0.005) (0.005) (0.006)
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Table 2
Contingency table of simulation underlying truth and tight clustering result with 6 target
modules. 0 represents the scattered gene group. 1 ∼ 6 represent 6 detected modules.
Bolded numbers are genes with correct assignment.
Module homo− homo+ ssp1− ssp1+ ssp2− ssp2+ non-DE
1 177 0 0 0 0 0 0
2 0 164 0 0 0 0 0
3 0 2 0 0 0 84 4
4 0 4 0 72 0 0 6
5 0 0 66 0 0 0 2
6 1 0 0 0 62 0 0
0 6 4 0 0 7 0 19
only in the second study with negative effect sizes (denoted as “ssp1−”).
The rest of the genes are not DE (denoted as “non-DE”). The biological
variance σ is set to 1 in this simulation.
We first applied the proposed method to this synthetic dataset. We con-
trolled FDR at 5% under DB and obtained 691 genes. These genes were
used as input for our gene module detection using the tight clustering algo-
rithm. We identified six gene modules in these 691 genes. The detected gene
modules are tabulated against the true gene modules simulated in table 2
(module 0 contains scattered genes not assigned to any of the six modules).
The detected gene modules clearly correspond to the true modules, and
most of the non-DE genes were left to the noises. The heatmaps, confidence
scores and DE patterns of these six modules are shown in supplementary
figure S2 (Huo, Song and Tseng, 2018). An alternative approach is to apply
tight clustering directly on the Z -statistics. By comparing the results, we
found that the modules detected by this naive approach are neither pure nor
distinguishable under our simulation settings [see details in supplementary
table S1 (Huo, Song and Tseng, 2018)].
3.3. Additional simulations on sample size effects. To assess impact of
unbalanced sample size, we simulated the following special scenarios with
1. different numbers of samples in different studies,
2. different numbers of cases and controls in each study,
3. different ratios of case and control samples in each study.
Below, we followed the simulation setting in section 3.1 unless otherwise
mentioned. In scenario 1, we allowed different studies to have different num-
bers of samples. Under this scenario, we simulated case (a), with the num-
bers of samples (case/control) being 20/20, 30/30, 40/40 for three studies
respectively, and case (b), with the numbers of samples (case/control) being
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20/20, 50/50, 100/100 respectively. In scenario 2, we allowed the numbers of
cases and controls to be different within each study. Under this scenario, we
simulated case (c), with the numbers of samples (case/control) being 60/20,
60/20, 60/20 for three studies respectively. In scenario 3, we allowed the ra-
tios of case and control samples to be different within each study. Under this
scenario, we simulated case (d), with the numbers of samples (case/control)
being 20/60, 40/40, 60/20 for three studies respectively.
The results of simulation cases (a)-(d) are shown in supplementary ta-
ble S2 (Huo, Song and Tseng, 2018). We observed that under scenario 1,
scenario 2, and scenario 3, BayesMP controlled FDR to its nominal level for
DA¯, DB, and Dr¯. These results indicate that our Bayesian model is robust
against impact of heterogeneity sample size in a wide spectrum of scenarios.
3.4. Additional simulations on robustness of the algorithm. In our Bayesian
hierarchical model, we assume that the null component f0 comes from N(0, 1)
— the theoretical null for all studies. However, this assumption can be
violated when genes from null components are correlated (Efron et al.,
2001). Therefore, we designed simulations to access the performance of
our model when theoretical null assumption is not valid. To be specific,
in our simulation setting step 2c, we varied the number of correlated clus-
ters C = 200, 300, 400, 500, representing increasing probability of correlated
null component. We evaluated the performance of the Bayesian hierarchical
model, and the result is shown in supplementary table S4 (Huo, Song and
Tseng, 2018). We observe that the BayesMP still performs very well even
though the null components are correlated. Therefore BayesMP is robust
against the theoretical null assumption for the null component.
4. Real data applications. To further evaluate our method and demon-
strate its usage, we applied BayesMP on three real meta-analysis exam-
ples: one on the gene expression of multi-tissue microarray studies using
metabolism-related knockout mice, one on multi-brain-region RNA-seq stud-
ies using HIV transgenic rats, and another on transcriptomic breast cancer
studies across multiple platforms. The sample size description is shown in
supplementary table S5 (Huo, Song and Tseng, 2018).
4.1. Mouse metabolism data. Very long-chain acyl-CoA dehydrogenase
(VLCAD) deficiency was found to be associated with energy metabolism
disorder in children (Li and Tseng, 2011). Two genotypes of the mouse
model — wild type (VLCAD +/+) and VLCAD-deficient (VLCAD −/−)
— were studied for three types of tissues (brown fat, liver, and heart) with
three to four mice in each genotype group. The total number of genes from
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these three transcriptomic microarray studies is 14,495. Supplementary ta-
ble S5(a) (Huo, Song and Tseng, 2018) shows details of the study design.
Two-sided p-values were calculated using limma by comparing wild-type
versus VLCAD-deficient mice in each tissue, and one-sided p-values were
obtained by considering the effect size direction. BayesMP took 62 minutes
to obtain 10,000 posterior samples using MCMC, and the first 500 posterior
samples were excluded as burn-in iterations. By controlling FDR at 5%, we
detected 168 probes under DA¯; among them, 156 have concordant effect size
directions in all the three tissues. The heatmap for the genes detected under
DA¯ is shown in supplementary figure S6 (Huo, Song and Tseng, 2018).
Similarly, under DB we obtained 3,496 DE genes at an FDR level of 5%
and 1,243 DE genes at an FDR level of 1%. Due to the unusually strong
genome-wide biological signal, we decided to use the FDR cutoff of 1% for
the downstream analysis to increase statistical power (of the Fisher’s exact
test) in pathway enrichment analysis. Then we applied the tight cluster-
ing algorithm using the cosine distance as described in section 2.4 to de-
tect modules based on 1,243 DE genes at the stringent FDR level of 1%.
The results are shown in figure 3. Using the tight clustering, we were able
to detect 6 gene modules with unique patterns. The first two biomarker
modules are consensus genes that are up-regulated or down-regulated in all
tissues. The next four modules are biomarkers with study-specific differ-
ential patterns. For example, DE genes in module III are up-regulated in
the heart but not in the brown fat or the liver. To examine the biological
functions of these modules, we performed pathway enrichment analysis for
genes in each module using Fisher’s exact test. The pathway database was
downloaded from the Molecular Signatures Database (MSigDB) v5.0 (http:
//bioinf.wehi.edu.au/software/MSigDB/), where a mouse-version path-
way database was created by combining pathways from KEGG, BIOCARTA,
REACTOME, and GO databases and mapping all the human genes to their
orthologs in mouse using Jackson Laboratory Human and Mouse Orthol-
ogy Report (http://www.informatics.jax.org/orthology.shtml). The
resulting p-values were converted to q-values by Benjamini-Hochberg cor-
rection (Benjamini and Hochberg, 1995) to adjust for multiple comparison,
where q-value measures the false discovery rate (FDR) one would incur by
accepting the given test. At an FDR cutoff of 5%, we summarized the path-
way detection result (see supplementary Excel file 1 for detailed pathway
information). Among the six gene modules with distinct DE patterns, mod-
ule I is enriched in enzyme pathways (e.g., KEGG lysosome; q = 1.6×10−3),
module II is enriched in pathways for lyase activity (e.g., GO lyase activ-
ity; q = 0.26), module III is enriched in defense response pathways (e.g.,
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GO defense response pathway; q = 2.2 × 10−6), module IV is enriched in
phosphatase regulator pathways (e,g, GO phosphatase regulator activity;
q = 0.12), module VI is enriched in platelet related pathways (e.g., GO for-
mation of platelet; q = 2.2 × 10−2). For module V, we didn’t detect any
enriched pathways. Remarkably, all of these pathways are known to be re-
lated to different aspects of metabolism, which indicates that our method is
able to detect homogeneous and heterogeneous gene modules that are biolog-
ically meaningful. The biomarker clustering result enhances meta-analysis
interpretation and motivates hypothesis for further biological investigation.
For example, it is intriguing to understand why VLCAD-mutation impacts
DE genes only up-regulated in the heart but not in the brown fat or the liver,
and why these genes are associated with the defense response pathway.
4.2. HIV transgenic rat RNA-seq data. Li et al. (2013) conducted studies
to determine gene expression differences between F344 and HIV transgenic
rats using RNA-seq (GSE47474 in the Gene Expression Omnibus database
[http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47474]). The
HIV transgenic rat model was designed to study learning, memory, vul-
nerability to drug addiction, and other psychiatric disorders vulnerable to
HIV-positive patients. They sequenced RNA transcripts with 12 F334 rats
and 12 HIV transgenic rats in prefrontal cortex (PFC), hippocampus (HIP),
and striatum (STR) brain regions [see detail in supplementary table S5(b)
(Huo, Song and Tseng, 2018)]. We applied the same alignment procedure
using TopHat (Trapnell, Pachter and Salzberg, 2009) adopted by Li et al.
(2013) and obtained the RNA-seq count data for 16,821 genes by BEDTools
(Quinlan and Hall, 2010). We filtered out genes with less than 100 total
counts within any brain region and ended up with 11,824 genes. We re-
moved potential outliers by checking the sample correlation heatmaps (sup-
plementary figure S7) (Huo, Song and Tseng, 2018). We employed R package
edgeR to perform DE gene detection and obtained two-sided p-values. The
one-sided p-values were obtained by considering the effect size directions
and further converted to Z statistics. It took 41 minutes to obtain 10,000
posterior samples via MCMC, and the first 500 posterior samples were ex-
cluded as burn-in iterations. Since it is well known that the postmortem
brain expression profiles generally contain weak signals, we controlled FDR
at 20% in the analysis. Under DA¯, we detected 69 genes, of which all 69
had concordant DE directions. The heatmaps of the expression levels (log
of normalized counts) of these genes in the three brain regions are shown
in supplementary figure S8 (Huo, Song and Tseng, 2018). Under DB, we
detected 669 genes. We further applied the tight clustering algorithm, and
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Fig 3. Six meta-pattern modules of biomarkers from the mouse metabolism example.
Each row shows a set of detected biomarkers showing similar meta-pattern of differential
signals. 3(a) Heatmaps of detected genes (on the rows) and samples (on the columns) for
each tissue (brown fat, heart, or liver), where each tissue represents a study (i.e., brown
fat for s = 1, heart for s = 2, liver for s = 3). The black color bar on top represents wild
type (control), and the red color bar on top represents VLCAD-deficient mice (case). 3(b)
Heatmaps of confidence scores (CS) (genes on the rows and three studies on the columns).
Confidence score is described in section 2.3, which ranges from −1 (blue color for down-
regulation) to 1 (red color for up-regulation). 3(c) Bar plots of mean posterior probability
for Ygs = 1 (red color for up-regulation) and Ygs = −1 (blue color for down-regulation)
for each module in each tissue. Error bar represents standard deviation across all genes
in the module. The number of genes is shown on top of each bar plot. In figure 3(b) and
3(c), we use “Brown” to denote “Brown fat”.
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obtained 3 gene modules. Their gene expression heatmaps, DE confidence
scores and bar plots of posterior probability of differential expression are
shown in figure 1. To examine the biological functions of these modules,
we also performed pathway enrichment analysis using the same procedure
as in section 4.1 (see supplementary Excel file 2 for detailed information).
As the postmortem brain expression profiles generally contain much weaker
signals and the gene size of each module is relatively small, we presented
p-values (unadjusted for multiple comparison) instead of q-values for the
below pathway enrichment analysis. According to the results, module I is
down-regulated in all three brain regions, and is enriched in pathways re-
lated to the immune system (e.g., REACTOME inntate immunity signaling;
p = 6.26× 10−3), module II is up-regulated in all three brain regions and is
enriched in pathways related to response to virus (e.g., GO response to virus;
p = 1.81× 10−3), module III is down-regulated in HIP, but up-regulated in
PFC and STR, and it is enriched in pathways related to synapsis (e.g., GO
synaptic transmission; p = 2.75×10−3) and neuron connections (e.g., KEGG
neuroactive ligand receptor interaction; p = 2.88 × 10−3). Since it is well-
known that HIV attacks the immune system (Weiss, 1993), we anticipate
genes for immune response to be down-regulated, as observed in module I.
The up-regulation of response to virus pathway we found in module II is
reasonable since the mice are infected by the virus. Moreover, because dif-
ferent brain regions have different functions, it is not surprising to discover
some neuron-related genes that may respond differently to HIV in different
brain regions (module III).
4.3. Breast cancer dataset. In this example, we combined seven breast
cancer transcriptomic datasets, which study the same biological problem
using different gene expression platforms, including Illuminia, Affymetrix
and RNA-seq. The phenotype of interest is the breast cancer grade, which
is defined according to the cancer cells’ growth patterns as well as their
appearance compared to to healthy breast cells. Grade I cancer cells show
slow and well-organized growth patterns and they look a little bit different
from healthy cells, while grade III cancer cells grow quickly in disorganized
patterns, with many dividing to make new cancer cells, which look very
different from healthy cells. Details of these 7 datasets are described in
supplementary table S5(c) (Huo, Song and Tseng, 2018). For each study, if
multiple probes match to the same gene, we select the probe with the largest
IQR (Gentleman et al., 2006) to represent the gene. After matching the same
gene symbols, 3,920 genes that appeared in all 7 studies were selected for
the analysis. For each study, we obtained two-sided p-values using limma
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(for continuous data) or edgeR (for count data) by comparing grade I versus
grade III with adjustment of race, age, and gender as covariates whenever
they were available. We calculated one-sided p-values by considering the
direction of the effect sizes. We applied BayesMP, and it took 31 minutes
to obtain 10,000 posterior samples using MCMC, and the first 500 posterior
samples were excluded as burn-in iterations.
Since we expect the studies combined in this application to be more ho-
mogeneous than previous examples, genes DE in most of the studies are
our major interest and worth further investigation. Moreover, because the
studies are conducted by different groups using different platforms, we want
our analysis to be robust against a couple of studies with poor quality or
unspecific probe design. We visualize the number of declared DE genes at
FDR 5% for Dr¯ (r = 1, . . . , 7) in figure 4. It is noticed that there is a no-
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Fig 4. Number of declared DE genes at FDR 5% for Dr¯ (r = 1, . . . , 7).
ticeable drop in the number of DE genes between r = 6 and r = 7. This
indicates that it could be too stringent to require that DE genes agree in all
seven studies. To make the DE gene detection replicable enough yet not too
stringent, we chose to use Dr¯ (r = 6). Under FDR 5%, we detected 1,437
significant genes. Pathway enrichment analysis was performed using Fisher’s
exact test. Top pathways associated with these genes are REACTOME cell
cycle (q = 0.0066) and REACTOME DNA replication (q = 0.0066). These
results are biologically meaningful since it is known that cancer cells’ growth
patterns of different grades are associated with cell cycle and DNA replica-
tion.
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We further performed a cross-study validation to assess the performance of
BayesMP. In each iteration, we set aside one study, applied BayesMP to the
remaining six studies, and declared DE genes under DA¯ using FDR=5%. To
evaluate the consistency of DE gene detection results between the BayesMP
of the six studies and the left-alone study, we calculated the area under
the curve (AUC) of the receiver operating characteristic (ROC) curves by
treating the DE status from BayesMP as a binary outcome and using the
p-values from the left-alone study to determine the moving sensitivity and
specificity. We repeated this procedure for each left-alone study to calculate
the AUC values. As a baseline contrast, for each left-alone single study, we
also similarly calculated AUC values using the DE status (using FDR = 5%)
from each of the other six individual studies, and calculated the average
and standard error of AUCs. As shown in supplementary table 6 (Huo,
Song and Tseng, 2018), the AUCs from BayesMP were between 0.65 and
0.85, consistently higher than the average AUCs from six individual studies
(ranging from 0.59 to 0.75), which shows quantitative validity of the meta-
analysis. Study GSE6532 has a relatively lower cross-study validation AUC
from BayesMP (= 0.65) than other studies, indicating lower compatibility
with other studies. This also justifies the usage of r = 6 for Dr¯ in the previous
paragraph.
5. Conclusion. For meta-analysis at the genome-wide level, the issues
to efficiently integrate information across studies and genes and to quantify
homogeneous and heterogeneous DE signals across studies have brought new
statistical challenges. The Bayesian hierarchical model provides a feasible
and effective solution. Compared to traditional hypothesis testing, decision
theory framework from Bayesian modeling provides a more flexible inference
to determine DE genes from meta-analysis. In this paper, we proposed a
Bayesian hierarchical model for general transcriptomic meta-analysis. From
posterior distribution of the latent variable (DE indicators Ygs), FDR is well
controlled, and there is no need to select different test statistics for different
hypothesis settings (HSA¯, HSB, and HSr¯). Post hoc clustering analysis on the
detected biomarkers generates biomarker modules of different meta-patterns
that facilitate biological interpretation and provides clues for hypothesis
generation and biological investigation.
Our proposed BayesMP framework has the following advantages. Firstly,
the model is simple, yet practical and powerful. The model is based on
one-sided p-values. This allows easy integration of data from different plat-
forms (for example, many different platforms from microarray and RNA-
seq). As a contrast, Scharpf et al. (2009) described a full Bayesian hierar-
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chical model for microarray meta-analysis, where the input data are mi-
croarray raw data (normalized intensities). Although such a full Bayesian
model theoretically best integrates all information and can be more pow-
erful, it cannot combine new RNA-seq platforms, since RNA-seq generates
count data versus continuous intensity measures in microarray. Such a full
hierarchical model also runs a greater risk of model mis-specification that in-
creases systemic bias across different microarray platforms. Our framework,
based on p-values, circumvents these difficulties and is powerful as long as
the method used to generate p-values in each study is effective. Secondly,
we adopted a conjugate Bayesian approach using DPs for alternative dis-
tributions f
(s)
±1 , which enables a mixture of multiple subgroups instead of
a single one-component alternative. DPs is nonparametric and thus robust
against model assumptions. The conjugacy of our model guarantees the fast
computing of the Gibbs sampling procedure. Thirdly, we have shown that
decision theory framework from BayesMP provides good FDR control and
power under different hypothesis settings (or decision spaces). Fourthly, in
contrast to the “hard” decision of 0 or 1 weights in AW-Fisher, the poste-
rior distributions of the DE indicators Ygs provide a stochastic quantification
and “soft” decision. For example, in the mouse metabolism example, gene
Mbnl2 (probeset 1422836 at) and gene Bcl2l11 (probeset 1435449 at) have
very similar p-values in the three studies: (0.0063, 0.16, 0.097) for Mbnl2 and
(0.0070, 0.16, 0.098) for Bcl2l11. Using AW, Mbnl2 ended up with a p-value
of 0.020 with weights (1, 0, 1), but Bcl2l11 had a p-value of 0.021 with weights
(1, 1, 1). A slight alteration of the p-value in the second study (heart tissue)
resulted in different weights. The posterior probabilities for these two genes
are, however, very similar, with (0.827, 0.561, 0.671) and (0.819, 0.561, 0.662)
respectively, and they belonged to the same gene module I in figure 3. The
stochastic quantification avoids sensitive 0 or 1 weight changes in AW-Fisher.
Finally, Fisher’s method does not categorize DE genes with homogeneous or
heterogeneous DE patterns across studies. In contrast, the improved AW-
Fisher method allows categorization of biomarkers but generates up to 2S−1
biomarker clusters, which becomes intractable when S is large. The posterior
probability of Ygs from BayesMP allows the application of tight clustering to
directly identify tight clusters of biomarkers with distinct DE meta-patterns.
Our simulation and three applications have shown good clustering accuracy
and improved interpretation of the biomarker modules.
BayesMP potentially has the following potential limitations. Computing is
often a consideration for Bayesian approaches. Our experiences have shown
that 10,000 simulations are sufficient to generate the posterior probabilities
in general, and less than 1 hour is enough for combining around 10, 000 genes
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using a regular desktop. For applications to much larger numbers of features
(e.g., SNPs or methylation sites in methyl-seq), parallel computing and/or
faster MCMC techniques will be needed.
Efron (2004) recommended to estimate an empirical null distribution for
the Z -statistics when the null distribution deviates from N(0, 1). In our sim-
ulation, we have shown that BayesMP with theoretical null generates robust
results when genes from null are correlated, a scenario violating the theo-
retical null assumption. We also found that BayesMP with empirical null is
slightly overconservative (actually FDR 1% while nominal FDR 5%) when
noise level is large. In our R package, we allow the users to choose from
using the theoretical null or the empirical null. However, the user should
check the assumptions made when estimating the empirical null distribu-
tions. For example, Efron (2004) assumes less than 10% DE genes and that
empirical null is also from a Gaussian distribution. This assumption needs
to be examined post hoc (e.g., examine whether the DE proportion is less
than 10% in each study given a relatively loose FDR control, say FDR <
10%). To explore whether theoretical or empirical null is more appropriate,
we also provide histograms for visual diagnosis [see supplementary figures
S4 and S5 (Huo, Song and Tseng, 2018) for details].
As mentioned in the introduction, batch effect correction and direct merg-
ing could be a viable alternative for meta-analysis if raw data are available
and batch effects can be accurately identified and corrected. Two major
types of batch effect correction methods have been widely studied in DE
analysis. The first type considers known batch information (aka unwanted
variation [UV] factors; e.g., experiments performed on different dates, by
different technicians, or on different platforms). Many methods have been
developed to correct for these known UVs (e.g. Johnson, Li and Rabinovic,
2007; Walker et al., 2008), and then samples can be directly merged for
so-called mega-analysis. The second type of batch correction assumes the
existence of unknown UV factors, in which case many methods (e.g. Leek
and Storey, 2007; Kang, Ye and Eskin, 2008; Listgarten et al., 2010) have
been developed to eliminate effects from unknown UV factors to improve
DE analysis. Since BayesMP takes p-values from single studies as input,
these methods can be easily adopted in each single study before implement-
ing BayesMP. However, it should be noted that over-correction can be a
potential concern for any batch correction method, and one should use with
caution (Jacob, Gagnon-Bartsch and Speed, 2016). In addition, such batch
correction is unnecessary if each study is from a single batch and there are
no other hidden factors within each study.
A prior for σ2c can be given to better characterize the variability in σ
2
c (e.g.,
26 Z. HUO ET AL.
truncated inverse gamma distribution; here, truncation such that σ2c ≥ 1 is
a sufficient condition such that density function of Z -statistics is monotone
with respect to Z ). However such a prior will make the Bayesian procedure
lose conjugacy. Therefore we fix σ2c = 1 to keep the algorithm computation-
ally efficient. Ghosal et al. (1999) illustrated that this procedure is equivalent
to choosing the bandwidth parameter a priori in kernel density estimation,
and established posterior consistency for it.
BayesMP is implemented in R calling C++. The BayesMP package is pub-
licly available at GitHub https://github.com/Caleb-Huo/BayesMP and
the authors’ websites.
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